Ahmed Bennis MD 🫀 @drbennisahmed

Mortality Reduction With SGLT2 + GLP-1 Therapy in T2D and Cardiovascular Disease @drbennisahmed hemostasistoday.com/science/cardio… #CardiovascularDisease #GLP1ReceptorAgonists #Hematology #Hemostasis #HemostasisToday #MedX #Medicine #SGLT2Inhibitors #Thrombosis #MedEd

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial Vericiguat showed a slight adjusted decrease in SBP and resulted in more symptomatic hypotension compared with placebo but was…

Moderate Secondary Mitral Regurgitation: Evolving Evidence and Management Strategies Moderate SMR is common in patients with HF, regardless of LVEF. A continuous relationship between the severity of SMR and the risk of mortality and HF hospitalizations has been demonstrated,…

Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial Selective in vitro enhancement of cardiac myosin motor function and myofilament force generation by danicamtiv prompted clinical evaluation. A short course of danicamtiv was…

Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology The evidence linking chronic, low-grade inflammation to the initiation and progression of ASCVD is robust, and several seminal randomized controlled clinical…

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction Treatment with digitoxin led to a lower combined risk of death from any cause or hospital admission for worsening heart failure than placebo among patients with heart failure and reduced ejection fraction who…

Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy Despite consistently lower voltage in women, no significant histopathological sex differences were identified in non-valvular cases, likely due to their inherently…

Automated Evaluation for Pericardial Effusion and Cardiac Tamponade with Echocardiographic Artificial Intelligence Our deep learning-based framework accurately grades pericardial effusion severity and detects cardiac tamponade from echocardiograms, demonstrating consistent…

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM At 96 weeks, NYHA improved by at least one class in 27 patients (79.4%), of whom 20 (58.8%) became asymptomatic, with reduction in severely…

Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis from ATTRibute-CM Acoramidis significantly reduced the cumulative burden of CV outcomes in ATTR-CM over 30 months @JACCJournals @ACCinTouch @MasriAhmadMD @CMichaelGibson…

Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990-2023 CVD remains the leading cause of disease burden and death worldwide with the greatest burden in low, low-middle, and middle SDI regions. @JACCJournals…

A Deep Learning-Based Pipeline for Large-Scale Echocardiography Data Curation and Measurements Potential of deep learning-based automated measurements in echocardiography for data mining in large real-world databases, paving the way for advancements in cardiac imaging research…

Predicting acute decompensated heart failure using circadian markers from heart rate time series Circadian metrics from a wrist-worn device showed progressive alterations over the 3 weeks preceding ADHF, offering potential early detection of HF decompensation with moderate…

Association of pre-admission exercise habit with post-discharge outcomes for older patients with heart failure Exercise habits before hospitalization were significantly associated with better strength and physical function and lower post-discharge all-cause mortality in older…

Sex differences in atrial fibrillation-related atrial remodelling assessed by electroanatomic mapping and biopsy Despite consistently lower voltage in women, no significant histopathological sex differences were identified in non-valvular cases, likely due to their inherently…

SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease In patients with T2D and ASCVD, treatment with SGLT2-I and GLP-1RA, especially in combination, is associated with a substantial reduction in mortality.…

Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population Metabolic dysfunction-associated steatotic liver disease is an independent risk factor for MACE and is associated with a significantly…

Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index SGLT-2i are ineffective in proteinuria reduction in patients with BMI<25 kg/m², which contrasts with the significant proteinuria reduction in overweight and obese patients…

Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis Despite less pronounced weight loss, patients with HFpEF, obesity, and type 2 diabetes responded…

2025 ACC/AHA Clinical Practice Guidelines Core Principles and Development Process: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines The process for developing ACC/AHA clinical practice guidelines summarized…